A structure of substrate-bound Synaptojanin1 provides new insights in its mechanism and the effect of disease mutations

Abstract

Synaptojanin1 (Synj1) is a phosphoinositide phosphatase, important in clathrin uncoating during endocytosis of presynaptic vesicles. It was identified as a potential drug target for Alzheimer's disease, Down syndrome and TBC1D24-associated epilepsy, while also loss-of-function mutations in Synj1 are associated with epilepsy and Parkinson's disease. Despite its involvement in a range of disorders, structural and detailed mechanistic information regarding the enzyme is lacking. Here, we report the crystal structure of the 5-phosphatase domain of Synj1. Moreover, we also present a structure of this domain bound to the substrate diC8-PI(3,4,5)P3, providing the first image of a 5-phosphatase with a trapped substrate in its active site. Together with an analysis of the contribution of the different inositide phosphate groups to catalysis, these structures provide new insights in the Synj1 mechanism. Finally, we analyzed the effect of three clinical missense mutations (Y793C, R800C, Y849C) on catalysis, unveiling the molecular mechanisms underlying Synj1-associated disease.

Data availability

Diffraction data have been deposited in the PDB under the accession code 7A0V and 7A17. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figure 4 and Figure 4 - figure supplements 1-3.

Article and author information

Author details

  1. Jone Paesmans

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3292-4609
  2. Ella Martin

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
  3. Babette Deckers

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
  4. Marjolijn Berghmans

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8699-6915
  5. Ritika Sethi

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
  6. Yannick Loeys

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
  7. Els Pardon

    Center for Structural Biology, VIB-VUB, Brussels, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2466-0172
  8. Jan Steyaert

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3825-874X
  9. Patrik Verstreken

    Department of Neurosciences, KU Leuven, Leuven, Belgium
    Competing interests
    Patrik Verstreken, Reviewing editor, eLife.
  10. Christian Galicia

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    For correspondence
    Christian.Galicia.Diaz.Santana@vub.be
    Competing interests
    No competing interests declared.
  11. Wim Versées

    Structural Biology Brussels, Vrije Universiteit Brussel, Brussel, Belgium
    For correspondence
    wim.versees@vub.be
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4695-696X

Funding

Fonds Wetenschappelijk Onderzoek (1S04918N)

  • Jone Paesmans

Fonds Wetenschappelijk Onderzoek (1S09120N)

  • Ella Martin

Fonds Wetenschappelijk Onderzoek (G0D3317N)

  • Patrik Verstreken
  • Wim Versées

Fonds Wetenschappelijk Onderzoek (11D4621N)

  • Babette Deckers

Vrije Universiteit Brussel (SRP50)

  • Wim Versées

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Paesmans et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,837
    views
  • 247
    downloads
  • 11
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Jone Paesmans
  2. Ella Martin
  3. Babette Deckers
  4. Marjolijn Berghmans
  5. Ritika Sethi
  6. Yannick Loeys
  7. Els Pardon
  8. Jan Steyaert
  9. Patrik Verstreken
  10. Christian Galicia
  11. Wim Versées
(2020)
A structure of substrate-bound Synaptojanin1 provides new insights in its mechanism and the effect of disease mutations
eLife 9:e64922.
https://doi.org/10.7554/eLife.64922

Share this article

https://doi.org/10.7554/eLife.64922

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    A Sofia F Oliveira, Fiona L Kearns ... Adrian J Mulholland
    Short Report

    The spike protein is essential to the SARS-CoV-2 virus life cycle, facilitating virus entry and mediating viral-host membrane fusion. The spike contains a fatty acid (FA) binding site between every two neighbouring receptor-binding domains. This site is coupled to key regions in the protein, but the impact of glycans on these allosteric effects has not been investigated. Using dynamical nonequilibrium molecular dynamics (D-NEMD) simulations, we explore the allosteric effects of the FA site in the fully glycosylated spike of the SARS-CoV-2 ancestral variant. Our results identify the allosteric networks connecting the FA site to functionally important regions in the protein, including the receptor-binding motif, an antigenic supersite in the N-terminal domain, the fusion peptide region, and another allosteric site known to bind heme and biliverdin. The networks identified here highlight the complexity of the allosteric modulation in this protein and reveal a striking and unexpected link between different allosteric sites. Comparison of the FA site connections from D-NEMD in the glycosylated and non-glycosylated spike revealed that glycans do not qualitatively change the internal allosteric pathways but can facilitate the transmission of the structural changes within and between subunits.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.